Kevin Kunzmann

A retrospective review of rural region's hospitals found that even the discharge time of day could be associated with a greater chance of readmission.

Gram-negative bacteria excluding Pseudomonas Aeruginosa has been associated with greater rates of patient mortality, vasopressor administration, and ICU admission.

Investigators found that treating for CSA in the patient population significantly decreases mortality risk—despite previous clinical warnings.

Investigators have shared new disparities of characteristics in men and women with differing severities of respiratory arousal threshold.

More IMPACT trial results shows Trelegy Ellipta has benefits for both reversible and nonreversible COPD patients in exacerbations and lung function versus dual therapy.

A new study found that Medicare Part D formulary shifts sometimes result in asthma patients forgoing controller therapy altogether.

A Dallas-based study found that an adult hospital with a universal screening policy was far more likely to provide screenings to high-risk patients aged 13 or older.

Originally approved by the FDA in 2006, the vaccine prevents certain cancers and diseases caused by the 9 types of HPV covered by the vaccine—an expansion from its originally-approved prevention of 4 different types.

A South Korea meta-analysis found that, similarly to C. difficile, tuberculosis risk could be limited by the lipid-lowering agent.

Roche's investigative drug could become the first single-dose oral antiviral approved for the US market in December.

In review of US-based infections during the 2016 outbreak, investigators found more telling indicators of the virus are patients' proximity to other infected patients, and their desire to be tested.

Streptococcus pneumoniae, the bacteria primarily behind CABP, is responsible for 1.2 million infections and 7000 deaths in the US annually.

Approximately 30% of annual HIV infections are caused by the subset of individuals unaware of their serostatus, and HCV rates have nearly tripled since 2011.

XYOSTED's approval comes nearly a year following Antares first received a Complete Response Letter from the FDA for its application.

Perampanel (FYCOMPA) has been approved for patients aged 4 years or older, who suffer from partial-onset seizures with or without secondarily generalized seizures, as both a tablet and oral suspension formulation.

Less than one-third received both influnza and Tdap vaccination during their pregnancies, citing limited understanding or assurance of their benefits and safety.

Investigators will assess the efficacy, safety, and tolerability of NanoFlu doses and formulations—both adjuvanted and unadjuvanted—in comparison to a pair of US marketed vaccines.

The Novartis humanized single-chain antibody fragment previously showed improved best corrected visual acuity in patients with nAMD versus aflibercept.

Patients treated with the RECELL Systems were required to donate 97.5% less skin than standard-of-care, and reported statistically significant reduction in patient-reported pain, increases in satisfaction, and improved outcomes in donor scars.

The FDA’s post-marketing review concludes a five-month speculation which began when CNN reported the Acadia Pharmaceutical antipsychotic therapy was associated with more than 700 deaths of patients with Parkinson disease since June 2016.

The latanoprost ophthalmic emulsion solution reduced intraocular pressure in patients by a mean 6-8 mmHg from baseline in clinical trials.

The FDA has been granting priority review to more pipeline drugs without skimping on application standards. What makes up a viable novel therapy application, specialty by specialty?

A meta-analysis shows the experimental therapy has favorable benefits for certain aspects of pain, as well as preferrable avenues of administration.

A quarter of surveyed second-year residents reported high emotional exhaustion and depersonalization. Nearly half reported weekly symptoms of burnout.

In results reported at the European Academy of Dermatology and Venereology Congress, two-week and four-week doses of the subcutaneous drug proved efficacious in improving patient skin.

Investigators reported an overall mean estimation error ranging from 3.47% to 5.29% in five-year outcomes for patients with AMD.

The FDA approved the Teva Pharmaceutical drug, just months after its phase 3 program for headache clusters was discontinued.

Novartis reported that 59% of patients at 24 weeks experienced little to no impact of their condition on their quality of life. Additionally, 87% of bio-naïve psoriasis patients remained on secukinumab through 12 months, indicating its tolerability in real-world settings.

The acceptance comes less than a month since the FDA had approved the anti-VEGF therapy for the treatment of wet AMD. Its mechanism of action allows it to block new blood vessel growth and the passing of fluids through blood vessels in the eye.

The company’s application for mepolizumab vied for it to serve as an add-on therapy to inhaled corticosteroid-based maintenance treatment in patients with COPD, as guided by patient blood eosinophil counts.